AcelRx presents SAP301 data at annual ASPS meeting

AcelRx Pharmaceuticals Inc. recently presented the subgroup analysis from the SAP301 clinical study by board-certified plastic surgeon and AcelRx clinical investigator Dr. Shankar Lakshman at the American Society of Plastic Surgeons (ASPS) annual meeting.

The SAP301 Phase 3 clinical study compared ARX-04 to a placebo for the treatment of patients with moderate-to-severe acute pain after undergoing ambulatory abdominal surgery.

The presentation by Dr. Lakshman featured the activity of ARX-04 that was observed in 80 of the 161 patients who took part in the study who had abdominoplasty surgery in which ARX-04 showed a substantial statistical improvement in patients over placebo, which helped the study meet its primary goal in effectiveness.

The presentation took place on Sept. 24 and was titled “Phase 3 Results of Sublingual Sufentanil 30 mcg for the Management of Post-Operative Pain Following Abdominoplasty Surgery.”

The authors of the presentation are Dr. Lakshman of Pasadena Surgeons in Pasadena, California; Dr. Harold Minkowitz, Memorial Hermann Memorial City Medical Center in Houston, Texas; Dr. Timothy Melson, Helen Keller Hospital in Sheffield, Alabama; and Dr. David Leiman, Victory Medical Center in Houston, Texas.